Usefulness of diagnostic laparoscopy with 5-aminolevulinic acid (ALA)-mediated photodynamic diagnosis for the detection of peritoneal micrometastasis in advanced gastric cancer after chemotherapy

PurposeSuccessful cases have shown that conversion surgery after chemotherapy improves the prognosis of advanced gastric cancer. However, it is necessary to carefully select patients who have no unresectable factors prior to surgery. We recently reported that diagnostic laparoscopy with photodynamic diagnosis using oral 5-aminolevulinic acid (ALA-PDD) is a promising tool for diagnosing early peritoneal metastasis in gastric cancer. We herein evaluated the usefulness of this technique for detecting peritoneal metastases of advanced gastric cancer after chemotherapy.MethodsDiagnostic laparoscopy using sequential white light (WL) and ALA-PDD observations was performed in 38 patients with advanced gastric cancer after chemotherapy. The sensitivity of ALA-PDD for detecting peritoneal disease was compared with that of WL. The relationship between the state of peritoneal metastasis assessed by ALA-PDD and a cytological examination of the peritoneal fluid was evaluated.ResultsTwelve of the 38 patients (32 %) were diagnosed with peritoneal metastases by conventional laparoscopy. However, laparoscopy with ALA-PDD detected peritoneal metastases in 4 (11 %) of the 26 remaining patients. Three of these 4 patients had negative cytological results from the evaluation of the peritoneal fluid.ConclusionsDiagnostic laparoscopy using ALA-PDD is a useful technique for detecting metastases and determining treatment strategies to select patients with advanced gastric cancer who have received chemotherapy.

[1]  S. Kim,et al.  The Result of Conversion Surgery in Gastric Cancer Patients with Peritoneal Seeding , 2014, Journal of gastric cancer.

[2]  Joon-Oh Park,et al.  Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Ajani,et al.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Ohtsu,et al.  Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP. , 2007, Japanese journal of clinical oncology.

[5]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[6]  Yoon-Koo Kang,et al.  Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Kristjan Plaetzer,et al.  ALA and its clinical impact, from bench to bedside , 2008, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[8]  P. Charlesworth,et al.  The use of 5-aminolevulinic acid (ALA) in photodynamic therapy (PDT). , 1993, Journal of photochemistry and photobiology. B, Biology.

[9]  D. Cunningham,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2010, The New England journal of medicine.

[10]  H. Katayama,et al.  Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria , 2015, Surgery Today.

[11]  R. Steiner,et al.  Fluorescence detection of small gastrointestinal tumours: principles, technique, first clinical experience , 2000, Langenbeck's Archives of Surgery.

[12]  T. Shuin,et al.  Comparison between intravesical and oral administration of 5‐aminolevulinic acid in the clinical benefit of photodynamic diagnosis for nonmuscle invasive bladder cancer , 2012, Cancer.

[13]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[14]  H. Kuwano,et al.  Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer , 2015, Annals of Surgical Oncology.

[15]  E. G. Hahn,et al.  Endoscopic photodynamic diagnosis: oral aminolevulinic acid is a marker of GI cancer and dysplastic lesions. , 1999, Gastrointestinal endoscopy.

[16]  Japanese Gastric Cancer Association.  Japanese gastric cancer treatment guidelines 2010 (ver. 3) , 2011, Gastric Cancer.

[17]  Gereon Hüttmann,et al.  Laparoscopic fluorescence detection of ovarian carcinoma metastases using 5‐aminolevulinic acid‐induced protoporphyrin IX , 2004, Cancer.

[18]  J. Kennedy,et al.  Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. , 1996, Journal of clinical laser medicine & surgery.

[19]  Osamu Ishikawa,et al.  Staging laparoscopy using ALA‐mediated photodynamic diagnosis improves the detection of peritoneal metastases in advanced gastric cancer , 2012, Journal of surgical oncology.

[20]  R. van Hillegersberg,et al.  Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: a study in patients with (pre)malignant lesions of the oesophagus. , 1998, British Journal of Cancer.

[21]  Hidenori Takahashi,et al.  Diagnostic Laparoscopy with 5-Aminolevulinic-Acid-Mediated Photodynamic Diagnosis Enhances the Detection of Peritoneal Micrometastases in Advanced Gastric Cancer , 2014, Oncology.

[22]  A. Nashimoto,et al.  The clinical significance of potentially curative resection for gastric cancer following the clearance of free cancer cells in the peritoneal cavity by induction chemotherapy , 2015, Surgery Today.